FIELD: biotechnology.
SUBSTANCE: invention relates to a method of determining whether a patient with hepatitis b (HBV) has an increased probability of a positive outcome of hepatitis B treatment compared to the average probability in a population of patients with hepatitis B. The proposed method includes establishing whether the sample with nucleic acid of specified patient with hepatitis B, associated with positive result of G allele of SNP rs 12356193.
EFFECT: invention allows you to determine whether a patient with HBV will respond to HBV therapy prior to therapy, and gives the possibility to avoid unnecessary expenditure and the emergence of side-effects and complications during treatment.
9 cl, 24 dwg, 3 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR TREATMENT OF HEPATITIS B INFECTION | 2018 |
|
RU2780021C2 |
| SINGLE NUCLEOTIDE POLYMORPHISM ON CHROMOSOME 15 ENABLING PREDICTION OF HCV TREATMENT RESPONSES | 2012 |
|
RU2606759C2 |
| PREDICTION OF KINETICS OF HEPATITIS C VIRUS IN INTERFERON-EXCLUDING TREATMENT | 2011 |
|
RU2590691C2 |
| SINGLE NUCLEOTIDE POLYMORPHISMS FOR PREDICTING RESULTS OF TREATMENT OF HEPATIC C VIRUS INFECTION | 2011 |
|
RU2567663C2 |
| METHOD AND MEANS FOR RAPID DETECTION OF HEPATITIS D VIRUS INFECTIONS | 2019 |
|
RU2800845C2 |
| METHOD OF MICROORGANISM DETECTION IN BIOLOGICAL SAMPLE | 2007 |
|
RU2435865C2 |
| GENETIC POLYMORPHISMS ACCOMPANYING AGE-RELATED MACULAR DEGENERATION | 2010 |
|
RU2546008C2 |
| HUMAN GENETIC MARKERS ASSOCIATED WITH RESPONSE TO TREATMENT AGENTS THAT TARGET TOXIN B CLOSTRIDIUM DIFFICILE | 2017 |
|
RU2761249C2 |
| MUTANT POLYMERASES OF HEPATITIS B VIRUS | 2012 |
|
RU2625021C2 |
| GENETIC MARKERS FOR PREDICTING SENSITIVITY TO THERAPY | 2014 |
|
RU2809215C2 |
